Why the study?
Hypertensive cardiac hypertrophy significantly contributes to heart failure, but the impact of aurantiamide acetate on hypertensive cardiac hypertrophy remains unclear.
Does aurantiamide acetate mitigate hypertensive cardiac hypertrophy and ER stress in in vitro and in vivo models?
Population
Ang II- and TM-treated H9C2 cardiomyoblasts and 2K1C hypertensive rats
Comparison
Aurantiamide acetate administration
Design
In vitro and in vivo preclinical animal and cell study
Authors
Loading...
Hypothesis-generating for aurantiamide acetate in hypertensive heart disease; leaves open clinical translation pending human data.
Does aurantiamide acetate mitigate hypertensive cardiac hypertrophy and ER stress in in vitro and in vivo models?
Aurantiamide acetate demonstrates therapeutic potential for hypertensive heart disease by mitigating cardiac hypertrophy through inhibition of MAPK signaling and ER stress.
Çeker et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: